表紙
市場調査レポート

Creabilis SA の製品パイプライン分析

Creabilis SA - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 320912
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Creabilis SA の製品パイプライン分析 Creabilis SA - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 30 Pages
概要

Creabilis SA はルクセンブルグに本社を持つバイオテクノロジー企業であり、皮膚炎や炎症疾患の局所治療薬を開発し商品化しています。慢性掻痒症など、QOLの低下を伴う皮膚の消耗性疾患に注力しており、イタリアで研究活動を行っています。

当レポートでは、Creabilis SA における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Creabilis SA の基本情報

  • Creabilis SA の概要
  • 主要情報
  • 企業情報

Creabilis SA :R&Dの概要

  • 主な治療範囲

Creabilis SA :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Creabilis SA :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Creabilis SA :薬剤プロファイル

  • CT-327
  • CT-340
  • CT-637
  • FP-7

Creabilis SA :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Creabilis SA :最新のパイプライン情報

Creabilis SA :開発休止中のプロジェクト

Creabilis SA :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07911CDB

Summary

Global Markets Direct's, 'Creabilis SA - Product Pipeline Review - 2015', provides an overview of the Creabilis SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Creabilis SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Creabilis SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Creabilis SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Creabilis SA's pipeline products

Reasons to buy

  • Evaluate Creabilis SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Creabilis SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Creabilis SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Creabilis SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Creabilis SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Creabilis SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Creabilis SA Snapshot
    • Creabilis SA Overview
    • Key Information
    • Key Facts
  • Creabilis SA - Research and Development Overview
    • Key Therapeutic Areas
  • Creabilis SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Creabilis SA - Pipeline Products Glance
    • Creabilis SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Creabilis SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Creabilis SA - Drug Profiles
    • CT-327
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-1x1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-1x2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-1x3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-340
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CT-352
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Kinase for Inflammatory Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Creabilis SA - Pipeline Analysis
    • Creabilis SA - Pipeline Products by Target
    • Creabilis SA - Pipeline Products by Route of Administration
    • Creabilis SA - Pipeline Products by Molecule Type
    • Creabilis SA - Pipeline Products by Mechanism of Action
  • Creabilis SA - Recent Pipeline Updates
  • Creabilis SA - Dormant Projects
  • Creabilis SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Creabilis SA, Key Information
  • Creabilis SA, Key Facts
  • Creabilis SA - Pipeline by Indication, 2015
  • Creabilis SA - Pipeline by Stage of Development, 2015
  • Creabilis SA - Monotherapy Products in Pipeline, 2015
  • Creabilis SA - Phase II, 2015
  • Creabilis SA - Preclinical, 2015
  • Creabilis SA - Pipeline by Target, 2015
  • Creabilis SA - Pipeline by Route of Administration, 2015
  • Creabilis SA - Pipeline by Molecule Type, 2015
  • Creabilis SA - Pipeline Products by Mechanism of Action, 2015
  • Creabilis SA - Recent Pipeline Updates, 2015
  • Creabilis SA - Dormant Developmental Projects,2015

List of Figures

  • Creabilis SA - Pipeline by Top 10 Indication, 2015
  • Creabilis SA - Pipeline by Stage of Development, 2015
  • Creabilis SA - Monotherapy Products in Pipeline, 2015
  • Creabilis SA - Pipeline by Top 10 Target, 2015
  • Creabilis SA - Pipeline by Top 10 Route of Administration, 2015
  • Creabilis SA - Pipeline by Top 10 Molecule Type, 2015
  • Creabilis SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top